Unicycive Therapeutics (UNCY)

Its lead program is oxylanthanum carbonate, commonly referred to as OLC, an investigational phosphate binder designed to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Hyperphosphatemia occurs when phosphate levels in the blood become elevated, a common complication for dialysis patients that can contribute to serious cardiovascular and bone-related problems. Phosphate binders are an established category, but Unicycive is seeking to differentiate OLC through its formulation and potential dosing profile.

The company is also advancing UNI-494, a drug candidate being studied for acute kidney injury. Acute kidney injury can develop rapidly in hospital settings and is associated with poor outcomes, particularly in vulnerable patients. By targeting this indication, Unicycive is pursuing a market with substantial unmet need and limited approved pharmacological therapies.

As a biotechnology company without a broad commercial portfolio, Unicycive’s investment profile is closely tied to clinical progress, regulatory milestones, financing needs, and the eventual market potential of its pipeline. Its strategy is to identify and develop renal disease assets that may address practical treatment challenges for nephrologists, dialysis providers, and patients.